Search results
Showing 1 to 15 of 313 results for gastrointestinal
Acute upper gastrointestinal bleeding in over 16s: management (CG141)
This guideline covers how upper gastrointestinal bleeding can be effectively managed in adults and young people aged 16 years and older. It aims to identify which diagnostic and therapeutic steps are useful so hospitals can develop a structure in which clinical teams can deliver an optimum service for people who develop this condition.
View recommendations for CG141Show all sections
All NICE products on upper gastrointestinal bleeding. Includes any guidance, advice and quality standards.
This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS38Show all sections
Sections for QS38
- Quality statements
- Quality statement 1: Risk assessment
- Quality statement 2: Immediate endoscopy for people who are haemodynamically unstable
- Quality statement 3: Endoscopy within 24 hours for people who are haemodynamically stable
- Quality statement 4: Endoscopic treatment for non-variceal bleeding
- Quality statement 5: Treatment of non-variceal bleeding after first or failed endoscopic treatment
- Quality statement 6: Prophylactic antibiotic therapy for variceal bleeding
- Quality statement 7: Band ligation for oesophageal variceal bleeding
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)
Evidence-based recommendations on imatinib (Glivec) for treating gastrointestinal stromal tumours in adults.
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development Reference number: GID-TA10089 Expected publication date: 15 November 2017
NICE is unable to make a recommendation on avapritinib (Ayvakit) for treating unresectable or metastatic gastrointestinal stromal tumours in adults. Blueprint Medicines will not be launching the technology in the UK and has confirmed it will withdraw its submission.
Show all sections
Sections for TA730
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Endoscopic submucosal dissection of lower gastrointestinal lesions (HTG212)
Evidence-based recommendations on endoscopic submucosal dissection of lower gastrointestinal lesions. This involves inserting a camera through the anus and injecting a solution to raise the affected area for removal.
View recommendations for HTG212Show all sections
Sections for HTG212
Assessing motility of the gastrointestinal tract using a wireless capsule (HTG351)
Evidence-based recommendations on assessing motility of the gastrointestinal tract using a wireless capsule. This involves swallowing a capsule that sends bowel information as it passes through the digestive system.
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach (HTG612)
Evidence-based recommendations on endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach. This involves removing a tumour using an endoscope and forceps. The aim is to remove the tumour without the need for open surgery.
View recommendations for HTG612Show all sections
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)
Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
NaviCam for diagnosing gastrointestinal tract conditions (MIB104)
NICE has developed a medtech innovation briefing (MIB) on NaviCam for diagnosing gastrointestinal tract conditions .